Neuro-oncology practice最新文献

{"title":"The predictive value of partial <i>MGMT</i> promoter methylation for IDH-wild-type glioblastoma patients.","authors":"Matthew Torre,&nbsp;Patrick Y Wen,&nbsp;J Bryan Iorgulescu","doi":"10.1093/nop/npac070","DOIUrl":"https://doi.org/10.1093/nop/npac070","url":null,"abstract":"<p><strong>Background: </strong>Glioblastoma patients with hypermethylation of the O⁶-methylguanine-methyltransferase (<i>MGMT</i>) gene promoter have significantly improved survival when treated with temozolomide compared to patients with unmethylation of the <i>MGMT</i> promoter. However, the prognostic and predictive significance of partial <i>MGMT</i> promoter methylation is unclear.</p><p><strong>Methods: </strong>The National Cancer Database was queried for patients newly diagnosed in 2018 with histopathologically confirmed isocitrate dehydrogenase (IDH)-wildtype glioblastoma. The overall survival (OS) associated with <i>MGMT</i> promoter methylation status was assessed using multivariable Cox regression with Bonferroni correction for multiple testing (<i>P</i> < .008 was significant).</p><p><strong>Results: </strong>Three thousand eight hundred twenty-five newly diagnosed IDH-wildtype glioblastoma patients were identified. The <i>MGMT</i> promoter was unmethylated in 58.7% (<i>n</i> = 2245), partially methylated in 4.8% (<i>n</i> = 183), hypermethylated in 3.5% (<i>n</i> = 133), and methylated not otherwise specified (NOS; likely consisting predominantly of hypermethylated cases) in 33.0% (<i>n</i> = 1264) of cases. Among patients that received first-line single-agent chemotherapy (ie likely temozolomide), compared to partial methylation (referent), <i>MGMT</i> promoter unmethylation was associated with worse OS (hazard ratio [HR] 1.94; 95% confidence interval [95 CI]: 1.54-2.44; <i>P</i> < .001) in multivariable Cox regression adjusted for major prognostic confounders. In contrast, a significant OS difference was not observed between partially methylated promoters and either hypermethylated (HR 1.02; 95 CI: 0.72-1.46; <i>P</i> = .90) or methylated NOS (HR 0.99; 95 CI: 0.78-1.26; <i>P</i> = .93) promoters. Among IDH-wildtype glioblastoma patients who did not receive first-line chemotherapy, <i>MGMT</i> promoter methylation status was not associated with significant differences in OS (<i>P</i> = 0.39-0.83).</p><p><strong>Conclusions: </strong>Compared to <i>MGMT</i> promoter unmethylation, partial methylation was predictive of improved OS among IDH-wildtype glioblastoma patients treated with first-line single-agent chemotherapy-supporting the use of temozolomide therapy in these patients.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 2","pages":"126-131"},"PeriodicalIF":2.7,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037633/pdf/npac070.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10193594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental diffuse low-grade gliomas: A systematic review and meta-analysis of treatment results with correction of lead-time and length-time biases.","authors":"Satoshi Nakasu,&nbsp;Yoko Nakasu,&nbsp;Atsushi Tsuji,&nbsp;Tadateru Fukami,&nbsp;Naoki Nitta,&nbsp;Hiroto Kawano,&nbsp;Akifumi Notsu,&nbsp;Kazuhiko Nozaki","doi":"10.1093/nop/npac073","DOIUrl":"https://doi.org/10.1093/nop/npac073","url":null,"abstract":"<p><strong>Background: </strong>Better overall survival (OS) reported in patients with incidental diffuse low-grade glioma (iLGG) in comparison to symptomatic LGG (sLGG) may be overestimated by lead-time and length-time.</p><p><strong>Methods: </strong>We performed a systematic review and meta-analysis of studies on adult hemispheric iLGGs according to the PRISMA statement to adjust for biases in their outcomes. Survival data were extracted from Kaplan-Meier curves. Lead-time was estimated by 2 methods: Pooled data of time to become symptomatic (LTs) and time calculated from the tumor growth model (LTg).</p><p><strong>Results: </strong>We selected articles from PubMed, Ovid Medline, and Scopus since 2000. Five compared OS between patients with iLGG (<i>n</i> = 287) and sLGG (<i>n</i> = 3117). The pooled hazard ratio (pHR) for OS of iLGG to sLGG was 0.40 (95% confidence interval [CI] {0.27-0.61}). The estimated mean LTs and LTg were 3.76 years (<i>n</i> = 50) and 4.16-6.12 years, respectively. The corrected pHRs were 0.64 (95% CI [0.51-0.81]) by LTs and 0.70 (95% CI [0.56-0.88]) by LTg. In patients with total removal, the advantage of OS in iLGG was lost after the correction of lead-time. Patients with iLGG were more likely to be female pooled odds ratio (pOR) 1.60 (95% CI [1.25-2.04]) and have oligodendrogliomas (pOR 1.59 [95% CI {1.05-2.39}]). Correction of the length-time bias, which increased the pHR by 0.01 to 0.03, preserved the statistically significant difference in OS.</p><p><strong>Conclusions: </strong>The reported outcome in iLGG was biased by lead-time and length-time. Although iLGG had a longer OS after correction of biases, the difference was less than previously reported.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 2","pages":"113-125"},"PeriodicalIF":2.7,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037942/pdf/npac073.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10661356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurosurgical care for patients with high-grade gliomas during the coronavirus disease 2019 pandemic: Analysis of routine billing data of a German nationwide hospital network.","authors":"Ruediger Gerlach, Julius Dengler, Andreas Bollmann, Michael Stoffel, Farid Youssef, Barbara Carl, Steffen Rosahl, Yu-Mi Ryang, Jorge Terzis, Rudolf Kristof, Thomas Westermaier, Ralf Kuhlen, Andreas Steinbrecher, Vincent Pellissier, Sven Hohenstein, Oliver Heese","doi":"10.1093/nop/npad015","DOIUrl":"10.1093/nop/npad015","url":null,"abstract":"<p><strong>Background: </strong>Little is known about delivery of neurosurgical care, complication rate and outcome of patients with high-grade glioma (HGG) during the coronavirus disease 2019 (Covid-19) pandemic.</p><p><strong>Methods: </strong>This observational, retrospective cohort study analyzed routine administrative data of all patients admitted for neurosurgical treatment of an HGG within the Helios Hospital network in Germany. Data of the Covid-19 pandemic (March 1, 2020-May 31, 2022) were compared to the pre-pandemic period (January 1, 2016-February 29, 2020). Frequency of treatment and outcome (in-hospital mortality, length of hospital stay [LOHS], time in intensive care unit [TICU] and ventilation outside the operating room [OR]) were separately analyzed for patients with microsurgical resection (MR) or stereotactic biopsy (STBx).</p><p><strong>Results: </strong>A total of 1763 patients underwent MR of an HGG (648 patients during the Covid-19 pandemic; 1115 patients in the pre-pandemic period). 513 patients underwent STBx (182 [pandemic]; 331 patients [pre-pandemic]). No significant differences were found for treatment frequency (MR: 2.95 patients/week [Covid-19 pandemic] vs. 3.04 patients/week [pre-pandemic], IRR 0.98, 95% CI: 0.89-1.07; STBx (1.82 [Covid-19 pandemic] vs. 1.86 [pre-pandemic], IRR 0.96, 95% CI: 0.80-1.16, <i>P</i> > .05). Rates of in-hospital mortality, infection, postoperative hemorrhage, cerebral ischemia and ventilation outside the OR were similar in both periods. Overall LOHS was significantly shorter for patients with MR and STBx during the Covid-19 pandemic.</p><p><strong>Conclusions: </strong>The Covid-19 pandemic did not affect the frequency of neurosurgical treatment of patients with an HGG based on data of a large nationwide hospital network in Germany. LOHS was significantly shorter but quality of neurosurgical care and outcome was not altered during the Covid-19 pandemic.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 5","pages":"429-436"},"PeriodicalIF":2.7,"publicationDate":"2023-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502769/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10672512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Society News","authors":"","doi":"10.1093/nop/npad011","DOIUrl":"https://doi.org/10.1093/nop/npad011","url":null,"abstract":"Journal Article Society News Get access Neuro-Oncology Practice, Volume 10, Issue 2, April 2023, Page 214, https://doi.org/10.1093/nop/npad011 Published: 24 March 2023 Article history Corrected and typeset: 24 March 2023 Published: 24 March 2023","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136126057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the reporting quality of adult neuro-oncology protocols, abstracts, and trials: Adherence to the SPIRIT and CONSORT statements.","authors":"Joshua S Suppree, Avni Patel, Sumirat M Keshwara, Sandhya Trichinopoly Krishna, Conor S Gillespie, George E Richardson, Mohammad A Mustafa, Sophia Hart, Abdurrahman I Islim, Michael D Jenkinson, Christopher P Millward","doi":"10.1093/nop/npad017","DOIUrl":"10.1093/nop/npad017","url":null,"abstract":"<p><strong>Background: </strong>Comprehensive and transparent reporting of clinical trial activity is important. The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 and Consolidated Standards of Reporting Trials (CONSORT) 2010 statements define the items to be reported in clinical trial protocols and randomized controlled trials, respectively. The aim of this methodological review was to assess the reporting quality of adult neuro-oncology trial protocols and trial result articles.</p><p><strong>Methods: </strong>Adult primary and secondary brain tumor phase 3 trial protocols and result articles published after the introduction of the SPIRIT 2013 statement, were identified through searches of 4 electronic bibliographic databases. Following extraction of baseline demographic data, the reporting quality of independently included trial protocols and result articles was assessed against the SPIRIT and CONSORT statements respectively. The CONSORT-A checklist, an extension of the CONSORT 2010 statement, was used to specifically assess the abstract accompanying the trial results article. Percentage adherence (standard deviation [SD]) was calculated for each article.</p><p><strong>Results: </strong>Seven trial protocols, and 36 trial result articles were included. Mean adherence of trial protocols to the SPIRIT statement was 79.4% (SD: 0.11). Mean adherence of trial abstracts to CONSORT-A was 75.3% (SD: 0.12) and trial result articles to CONSORT was 74.5% (SD: 0.10).</p><p><strong>Conclusion: </strong>The reporting quality of adult neuro-oncology trial protocols and trial result articles requires improvement to ensure comprehensive and transparent communication of planned neuro-oncology clinical trials and results within the literature. Raising awareness by clinical triallists and implementing mandatory evidence of proof of adherence by journals should improve reporting quality.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 4","pages":"391-401"},"PeriodicalIF":2.7,"publicationDate":"2023-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10184113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DICER1-associated central nervous system sarcoma: A comprehensive clinical and genomic characterization of case series of young adult patients.","authors":"Andrés F Cardona, Diego Fernando Chamorro Ortiz, Alejandro Ruíz-Patiño, Diego Gomez, Álvaro Muñoz, Dora V Ardila, Juan Esteban Garcia-Robledo, Camila Ordóñez-Reyes, Liliana Sussmann, Andrés Mosquera, Yency Forero, Leonardo Rojas, Fernando Hakim, Enrique Jimenez, Juan Fernando Ramón, Hernando Cifuentes, Diego Pineda, Juan Armando Mejía, July Rodríguez, Pilar Archila, Carolina Sotelo, Darwin A Moreno-Pérez, Oscar Arrieta","doi":"10.1093/nop/npad014","DOIUrl":"10.1093/nop/npad014","url":null,"abstract":"<p><strong>Background: </strong><i>DICER1</i> alterations are associated with intracranial tumors in the pediatric population, including pineoblastoma, pituitary blastoma, and the recently described \"primary <i>DICER1</i>-associated CNS sarcoma\" (DCS). DCS is an extremely aggressive tumor with a distinct methylation signature and a high frequency of co-occurring mutations. However, little is known about its treatment approach and the genomic changes occurring after exposure to chemoradiotherapy.</p><p><strong>Methods: </strong>We collected clinical, histological, and molecular data from eight young adults with DCS. Genomic analysis was performed by Next-generation Sequencing (NGS). Subsequently, an additional germline variants analysis was completed. In addition, an NGS analysis on post-progression tumor tissue or liquid biopsy was performed when available. Multiple clinicopathological characteristics, treatment variables, and survival outcomes were assessed.</p><p><strong>Results: </strong>Median age was 20 years. Most lesions were supratentorial. Histology was classified as fusiform cell sarcomas (50%), undifferentiated (unclassified) sarcoma (37.5%), and chondrosarcoma (12.5%). Germline pathogenic <i>DICER1</i> variants were present in two patients, 75% of cases had more than one somatic alteration in <i>DICER1</i>, and the most frequent commutation was <i>TP53</i>. Seven patients were treated with surgery, Ifosfamide, Cisplatin, and Etoposide (ICE) chemotherapy and radiotherapy. The objective response was 75%, and the median time to progression (TTP) was 14.5 months. At progression, the most common mutations were in <i>KRAS</i> and <i>NF1</i>. Overall survival was 30.8 months.</p><p><strong>Conclusions: </strong>DCS is an aggressive tumor with limited therapeutic options that requires a comprehensive diagnostic approach, including molecular characterization. Most cases had mutations in <i>TP53</i>, <i>NF1</i>, and <i>PTEN,</i> and most alterations at progression were related to <i>MAPK</i>, <i>RAS</i> and <i>PI3K</i> signaling pathways.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 4","pages":"381-390"},"PeriodicalIF":2.7,"publicationDate":"2023-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9816642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuro-oncology is a team sport: Is it time we added lifestyle coaches?","authors":"Jennie W Taylor","doi":"10.1093/nop/npad012","DOIUrl":"10.1093/nop/npad012","url":null,"abstract":"","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 3","pages":"217-218"},"PeriodicalIF":2.4,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10180364/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9530408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practice variation in re-resection for recurrent glioblastoma: A nationwide survey among Dutch neuro-oncology specialists.","authors":"Mark P van Opijnen, Filip Y F de Vos, Rob J A Nabuurs, Tom J Snijders, Rishi D S Nandoe Tewarie, Walter Taal, Joost J C Verhoeff, Jacobus J M van der Hoeven, Marike L D Broekman","doi":"10.1093/nop/npad016","DOIUrl":"10.1093/nop/npad016","url":null,"abstract":"<p><strong>Background: </strong>Despite current best treatment options, a glioblastoma almost inevitably recurs after primary treatment. However, in the absence of clear evidence, current guidelines on recurrent glioblastoma are not well-defined. Re-resection is one of the possible treatment modalities, though it can be challenging to identify those patients who will benefit. Therefore, treatment decisions are made based on multidisciplinary discussions. This study aimed to investigate the current practice variation between neuro-oncology specialists.</p><p><strong>Methods: </strong>In this nationwide study among Dutch neuro-oncology specialists, we surveyed possible practice variation. Via an online survey, 4 anonymized recurrent glioblastoma cases were presented to neurosurgeons, neuro-oncologists, medical oncologists, and radiation oncologists in The Netherlands using a standardized questionnaire on whether and why they would recommend a re-resection or not. The results were used to provide a qualitative analysis of the current practice in The Netherlands.</p><p><strong>Results: </strong>The survey was filled out by 56 respondents, of which 15 (27%) were neurosurgeons, 26 (46%) neuro-oncologists, 2 (4%) medical oncologists, and 13 (23%) radiation oncologists. In 2 of the 4 cases, there appeared to be clinical equipoise. Overall, neurosurgeons tended to recommend re-resection more frequently compared to the other specialists. Neurosurgeons and radiation oncologists showed opposite recommendations in 2 cases.</p><p><strong>Conclusions: </strong>This study showed that re-resection of recurrent glioblastoma is subject to practice variation both between and within neuro-oncology specialties. In the absence of unambiguous guidelines, we observed a relationship between preferred practice and specialty. Reduction of this practice variation is important; to achieve this, adequate prospective studies are essential.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 4","pages":"360-369"},"PeriodicalIF":2.7,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10184114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Caregivers matter: Neurological vulnerability for pediatric brain tumor survivors.","authors":"Emily L Moscato, Allison P Fisher, Natasha Pillay-Smiley, Ralph Salloum, Shari L Wade","doi":"10.1093/nop/npad010","DOIUrl":"10.1093/nop/npad010","url":null,"abstract":"<p><strong>Background: </strong>Pediatric brain tumor survivors (PBTS) are at risk of worse quality of life (QOL) due to the impact of neurotoxic treatments on the developing nervous system. Parenting factors such as protectiveness have been linked to worse QOL in childhood cancer survivors generally, but have yet to be explored for PBTS. We examined whether parenting behaviors moderated the association between neurotoxic treatment and QOL for PBTS.</p><p><strong>Methods: </strong>PBTS (<i>n</i> = 40; ages 10-25) and their caregivers (<i>n</i> = 47) completed measures of parenting behaviors including warmth (support/connectedness) and psychological control (protectiveness) and QOL. We divided the sample into moderate/high and low neurotoxicity groups based on chart review using the Pediatric Neuro-Oncology Rating of Treatment Intensity and examined moderator effects.</p><p><strong>Results: </strong>Survivor-reported primary caregiver warmth moderated the relationship between neurotoxicity and caregiver-reported QOL. Moderate/high neurotoxicity was associated with lower caregiver-reported QOL only when survivor-reported primary caregiver warmth was low, <i>P</i> = .02. Similar results were found for survivor-reported QOL. Caregiver-reported psychological control moderated the association between neurotoxicity and caregiver-reported QOL such that neurotoxicity only affected QOL at high levels of psychological control, <i>P</i> = .01.</p><p><strong>Conclusions: </strong>Heightened associations between parenting and QOL in the context of neurotoxic treatments underscore the need to better support PBTS. Findings are consistent with research suggesting that family factors may be particularly important for children with other neurological insults. Limitations include cross-sectional design and a small/heterogeneous clinical sample with low ethnic/racial diversity. Prospective studies are needed to refine evidence-based screening and develop psychosocial intervention strategies to optimize QOL for PBTS and their families.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 5","pages":"418-428"},"PeriodicalIF":2.7,"publicationDate":"2023-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10360414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The natural history of incidental meningiomas.","authors":"Elmira Hassanzadeh, Raymond Y Huang","doi":"10.1093/nop/npad009","DOIUrl":"10.1093/nop/npad009","url":null,"abstract":"","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 3","pages":"215-216"},"PeriodicalIF":2.4,"publicationDate":"2023-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10180354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9530404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}